Alto Pharmacy vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Alto Pharmacy is a full-service digital pharmacy delivering prescriptions to patients with a tech-enabled experience that coordinates with providers and insurance.
About
Alto Pharmacy is a digital pharmacy company founded in 2015 that provides a tech-enabled prescription delivery experience for patients managing ongoing medications and specialty drugs. The company differentiates from traditional pharmacies through proactive care coordination, where pharmacy staff work with patients and prescribers to address insurance prior authorizations, copay assistance programs, and adherence support rather than requiring patients to navigate these barriers themselves. Alto serves both retail pharmacy customers and specialty pharmacy customers managing complex medications for conditions including fertility, oncology, HIV, and mental health. The company raised over $350M and delivers to patients in multiple major US metropolitan areas. Alto's platform integrates with electronic health record systems to receive prescriptions digitally and provides prescribers with real-time visibility into whether patients have filled their medications. The company has positioned its proactive, high-touch model as particularly valuable for specialty drugs where adherence, insurance navigation, and side effect management require more support than standard retail pharmacies provide. Alto Pharmacy serves as an alternative to incumbent pharmacy benefit managers for employers and health plans that want better specialty pharmacy management.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.